Can a Patient Take Alli (Orlistat) with Lexapro and Wellbutrin?
Yes, a patient can safely take Alli (orlistat) with Lexapro (escitalopram) and Wellbutrin (bupropion) as there are no clinically significant drug-drug interactions between these medications.
Evidence for Safety of This Combination
The combination of orlistat with both escitalopram and bupropion is supported by pharmacokinetic data and clinical experience:
No Pharmacokinetic Interactions
A dedicated pharmacokinetic study specifically evaluated orlistat's interaction potential with multiple medications at therapeutic doses 1. The study demonstrated that orlistat does not affect the absorption, metabolism, or elimination of concomitant medications (with the notable exception of cyclosporine, which is not relevant here). The statistical analysis showed bioequivalence with 90% confidence intervals entirely within the acceptable range of 0.80 to 1.25 for both AUC and Cmax parameters 1.
Clinical Experience with Psychotropic Medications
A case series specifically examined orlistat use in patients taking psychotropic medications, including antidepressants 2. The study found that orlistat was safe, well-tolerated, and effective when combined with psychiatric medications, with patients achieving meaningful weight loss (average 35% weight reduction over 3 months) without adverse drug interactions 2.
Combination of Bupropion with SSRIs
The combination of bupropion (Wellbutrin) with SSRIs like escitalopram (Lexapro) is well-established in clinical practice 3. This combination is commonly used to enhance antidepressant response or counteract SSRI-associated sexual dysfunction, and the available data confirm this combination is generally well-tolerated 3.
Important Clinical Considerations
Timing of Orlistat Administration
- Take orlistat during or within 1 hour after meals containing fat 4
- If a meal is very low in fat, the orlistat dose can be omitted 4
Mandatory Vitamin Supplementation
Patients must take a daily multivitamin containing fat-soluble vitamins (A, D, E, K) at least 2 hours apart from orlistat 4. This is critical because orlistat's mechanism of blocking fat absorption can lead to deficiencies in fat-soluble vitamins.
Expected Side Effects
Gastrointestinal side effects are the primary concern with orlistat, not drug interactions:
- Flatulence, oily spotting/stools, fecal urgency, and fecal incontinence are common 4
- These effects are related to orlistat's mechanism of action (blocking fat absorption) and occur in isolation from the psychiatric medications 5
Monitoring Parameters
While taking this combination:
- Monitor blood pressure and heart rate periodically due to bupropion (especially in first 12 weeks) 4
- Watch for neuropsychiatric effects from bupropion, particularly in patients under 24 years 4
- Regular weight monitoring to assess efficacy
Important Caveats
Modest Weight Loss Expectations
Current guidelines actually recommend against routine use of orlistat due to modest efficacy (2.8-4.8% mean weight loss) and frequent GI side effects 5, 4. However, orlistat may be appropriate when other anti-obesity medications are contraindicated, unavailable, or unaffordable 5.
Alternative Consideration
Interestingly, naltrexone-bupropion ER is an FDA-approved combination specifically for obesity management 5, 4. Since the patient is already taking bupropion (Wellbutrin), this represents an existing therapeutic component. However, the naltrexone-bupropion formulation uses specific extended-release dosing that differs from standard bupropion prescribing.
Seizure Risk with Bupropion
Bupropion should be avoided in patients with seizure disorders and used cautiously in those at risk for seizures 4. This precaution applies regardless of orlistat use.
Bottom Line
There are no contraindications or clinically significant interactions between orlistat, escitalopram, and bupropion. The patient can safely take all three medications together, provided they adhere to the vitamin supplementation requirement and are prepared for orlistat's gastrointestinal side effects. The decision to use orlistat should be based on whether the patient values the modest potential weight loss benefit over the high likelihood of GI adverse effects 4.